<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>CCL20 is expected to play a crucial role in the initiation of immune responses and <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumour growth</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, expression of CCL20 in Epstein-Barr virus (EBV)-associated diseases has not been studied </plain></SENT>
<SENT sid="2" pm="."><plain>We examined the contribution of <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> and EBV-encoded latent membrane protein (LMP)-1 to CCL20 expression </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> and LMP-1 induced CCL20 <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression in the EBV-negative Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) cell lines and the embryonic kidney cell line </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="15358">Histone</z:chebi> deacetylase inhibitor-stimulated endogenous LMP-1 also induced CCL20 expression in an EBV-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell line </plain></SENT>
<SENT sid="5" pm="."><plain>Analysis of the CCL20 promoter showed that it was activated by LMP-1 C-terminal activation region (CTAR)-1 and CTAR-2 </plain></SENT>
<SENT sid="6" pm="."><plain>Co-expression of IkappaB alpha, IkappaB beta, IkappaB kinase (IKK)alpha, IKKbeta, IKKgamma, nuclear factor (NF)-kappaB-inducing kinase and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor receptor-associated factor 2 dominant-negative constructs with LMP-1 inhibited the activation of the CCL20 promoter by LMP-1, suggesting that LMP-1 induces CCL20 via NF-kappaB signalling </plain></SENT>
<SENT sid="7" pm="."><plain>The requirement for the NF-kappaB-binding site in the CCL20 promoter in LMP-1 responsiveness was established </plain></SENT>
<SENT sid="8" pm="."><plain>Our results indicate that activation of the NF-kappaB pathway by LMP-1 is required for the activation of CCL20 expression </plain></SENT>
</text></document>